Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Gains Orion's Branded Generics Fareston And Eldepryl For China; Oncology Sales Force Can Be Seen In Action In Advance Of Halaven

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Eisai Inc. is tapping into China's opportunities for branded generics. The company announced July 13 it acquired marketing and distribution rights for Orion Corp.'s breast cancer drug Fareston (toremifene) and Parkinson's disease drug Eldepryl (selegiline), both of which are available as generics in China
Advertisement

Related Content

Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
Eisai Revises Global Sales Strategy; Slashes U.S. Staff, Finds Ways To Retain Chinese Workers
Eisai Revises Global Sales Strategy; Slashes U.S. Staff, Finds Ways To Retain Chinese Workers
Advertisement
UsernamePublicRestriction

Register

SC078485

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel